Plain-English translation of NCT07542145 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether MDMA—a medication used in a controlled therapy setting—can help treat bulimia nervosa, an eating disorder involving cycles of binge eating and purging. Researchers want to see if this medication, combined with specialized therapy sessions, works better than standard therapy alone for people whose bulimia has not improved with previous treatment.
Current treatments for bulimia nervosa don't work for everyone, and many people continue to struggle even after trying standard therapy programs. This trial is exploring whether this medication, given in a carefully supervised therapeutic environment, might help people process difficult emotions and thoughts that fuel their eating disorder in a new way.
You likely qualify if…
You likely don't qualify if…
You would be assigned to one of three groups: two groups receive three doses of the medication spaced 3 weeks apart, each followed by therapy sessions to process your experience (one type of therapy is general, the other focuses specifically on bulimia), plus 12 additional weekly counseling sessions; or you would receive 22 weeks of standard weekly therapy. All participants have screening visits, baseline assessments, and a follow-up visit 6 months after starting. Sessions are recorded, and you'll need to report any health changes to the research team.
AI-generated summary from trial data · Jun 26, 2026 · Not medical advice
United States